Human Anti-SARS-CoV-2 Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb

Antibodies

Recombinant Human anti-SARS-CoV-2 Spike Protein Receptor Binding Domain, Tixagevimab (AZD8895), is expressed in XtenCHO.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped, positive-sense, single-stranded RNA virus that causes coronavirus disease 2019 (COVID -19). The structural proteins of SARS-CoV-2 include the envelope protein (E), spike or surface glycoprotein (S), membrane protein (M) and the nucleocapsid protein (N). The spike glycoprotein is found on the outside of the virus particle and gives coronavirus viruses their crown-like appearance. Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Surface glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

Recognizes SARS-CoV-2 Spike-RBD protein

Spike glycoprotein

Protein A affinity chromatography